Angiocard

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Angiocard

Quick Facts

Property Description
Active ingredient Nitroglycerin (Glyceryl trinitrate)
Forms Sublingual tablets, aerosol spray, transdermal patches, solution for injection
Pharmacological Class Organic Nitrate; Vasodilator
Common Use Managing chest discomfort related to heart conditions
Origin Synthetic

Angiocard: Definition and Pharmacological Class

Angiocard is the trade name for the compound Nitroglycerin, known internationally as Glyceryl trinitrate. This medication is a synthetic, single-ingredient drug classified as an Organic Nitrate and functions as a primary vasodilator. Organic Nitrates are distinct within cardiovascular pharmacology because their core mechanism involves acting as a Nitric oxide (NO) donor within the body, which is the fundamental signaling molecule for relaxing vascular smooth muscle. This class of medicine is recognized for its rapid and effective action in acute vascular events. This classification highlights the drug's potent ability to reduce pressure within the circulatory system, which is a primary feature of its clinical use.

Composition, Forms, and Delivery Profile

This medication is a single-ingredient product where the active substance, Nitroglycerin, is delivered via diverse dosage form(s) to achieve varying therapeutic goals. It is available as sublingual tablets, an aerosol spray, and transdermal patches, facilitating administration via sublingual, intravenous, or transdermal routes. The sublingual forms are distinguished by their rapid onset, a characteristic often utilized when immediate symptomatic relief is required, such as in a scenario of acute, unexpected chest discomfort. Conversely, the transdermal patch offers an extended-release profile for sustained systemic effect. The formulation for different brands will vary mainly in their excipients and delivery systems, though the active ingredient remains the same.

General Purpose of the Nitroglycerin Class

The general therapeutic purpose of Angiocard is to effectively mediate the relationship between the heart muscle's oxygen needs and the available supply. The drug achieves this benefit through venodilation (widening of veins) and concurrent coronary artery dilation, which work together to reduce the heart's workload while simultaneously improving its oxygenation. This strategic physiological action provides the general therapeutic benefit of balancing the heart's oxygen supply and demand.

What side effects are possible with Angiocard?

Possible Side Effects and Safety Information for Angiocard

Official regulatory documents emphasize that Angiocard, an implantable total artificial heart system, carries several serious and clinically significant adverse risks associated with mechanical circulatory support and device implantation.

Serious and Clinically Significant Adverse Reactions

The most serious documented events include:

  • Vascular Events: Stroke (which may be incapacitating or fatal), thrombosis (blood clot formation), and hemorrhage (bleeding) that may require surgical intervention.
  • Infection: Systemic infection, particularly during the initial post-operative recovery period.
  • Organ Dysfunction: Complications involving the kidneys, liver, and lungs, requiring medical treatment.
  • Device Failure: The possibility of the device stopping suddenly, a life-threatening event.
  • Procedural Risk: The need for additional major surgery, such as to replace the internal battery or Transcutaneous Energy Transmission (TET) unit.

Safety Restrictions and Contraindications

Angiocard is contraindicated (should not be used) in patients who have pre-existing, irreversible organ failure that would compromise long-term survival. Use is also restricted by anatomical assessment, where a patient's thoracic volume cannot physically accommodate the device, and by inadequate psychosocial support.

Safety Monitoring and Device Limitations

Specific safety protocols must be followed to ensure the device's function. The system features alarms, such as an internal low battery alarm, which mandate immediate action (TET attachment). Patients with the device are strictly prohibited from entering areas with high magnetic fields, such as those associated with Magnetic Resonance Imaging (MRI), as this could interfere with the device's operation.

Overdose and Emergency Response

Angiocard Overdose and When to Seek Help

Overdose with Angiocard (Nitroglycerin) primarily manifests as an exaggeration of its potent vasodilatory effects. The most common officially documented signs include severe, prolonged hypotension (a dangerous drop in blood pressure), a persistent throbbing headache, dizziness, vertigo, and syncope (fainting). Other clinical manifestations noted in regulatory documents involve skin flushing followed by the skin becoming cold and cyanotic, severe palpitations, and significant nausea and vomiting.

Severe Manifestations and Outcomes

Potential severe or life-threatening outcomes documented in regulatory sources include circulatory collapse and rare but possible Methemoglobinemia—a condition impairing the blood’s oxygen-carrying capacity. More serious neurological effects such as convulsions and coma are also officially noted.

Immediate Emergency Actions

Immediate medical attention is required for any suspected overdosage. Government guidance mandates that you contact emergency services or a certified Poison Help hotline right away.

Management for an overdose is defined as symptomatic and supportive. The regulatory information notes specific procedures such as elevation of the extremities and central volume expansion (intravenous fluids) to counteract severe hypotension. While no specific antidote is known for a direct overdose, Methylene blue is documented as the required treatment for Methemoglobinemia. Hospital monitoring is required for assessment and observation.

Therapeutic Uses of Angiocard

Angiocard is commonly used in situations involving certain distressing symptoms. It provides support that helps ease the overall symptom burden and may help patients cope more steadily with symptom fluctuations, relevant when symptoms lead to temporary functional strain or discomfort. Supportive agents are considered relevant when managing symptoms that interfere with daily functioning.

The medication is relevant for easing symptoms that interfere with daily functioning, such as symptoms related to physical discomfort or symptoms that create noticeable physiological strain. It is used across conditions presenting with acute episodes and those involving episodic or fluctuating manifestations.

“Angiocard is applied across domains where additional symptomatic support is needed, assisting with maintaining functional stability.”


Supportive Care for Episodic Discomfort

This domain helps address symptom clusters that may become intense or disruptive and interfere with daily comfort. Angiocard is relevant in contexts marked by increased discomfort or tension, where additional symptomatic support is needed.

Quick Fact: Relief for Symptom Clusters This use is commonly applied to symptom clusters that create noticeable physiological strain, supporting the patient during difficult episodes by easing distress.

Stabilization During Functional Strain

Angiocard is applied in scenarios where additional management of discomfort is required, particularly where symptoms create noticeable physiological strain. It may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Regulatory References

  1. MedlinePlus Medical Encyclopedia overview on Heart Failure Medications

Eligibility and Restrictions for Use

Who Can and Cannot Use Angiocard?

Angiocard (Nitroglycerin) eligibility is defined by strict regulatory criteria focusing on absolute prohibitions and population-specific restrictions. The standard approved population for use in angina pectoris is Adults.


Contraindications (Must Not Use)

The medicine is absolutely contraindicated in individuals taking certain medications, including Phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil) or soluble guanylate cyclase (sGC) stimulators (e.g., riociguat). Use is also prohibited in patients with severe anemia, conditions causing increased intracranial pressure, or states of acute circulatory failure or shock. Absolute contraindications also apply to individuals with known hypersensitivity to nitrates.


Conditional Use and Restrictions

Use in pediatric patients is not established for safety and effectiveness and is generally not recommended. Older adults are eligible but require caution due to a greater likelihood of decreased organ function. Restrictions also apply to organ function: patients with severe renal or hepatic insufficiency may use the medicine but require additional monitoring. During pregnancy and lactation, use is only permitted if clearly needed, as data is limited.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documentation structures the interaction profile of Angiocard (Nitroglycerin) based on severe pharmacodynamic reinforcement and altered systemic exposure of co-administered drugs.

Classification Interacting Substances/Categories
Formally Contraindicated Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil); Soluble Guanylate Cyclase (sGC) Stimulators (Riociguat).
Additive Hypotensive Effects Other Antihypertensive Drugs (e.g., Beta-blockers, Calcium Channel Blockers, Phenothiazines); Alcohol (Ethanol).

Official Interaction Statements and Rules:

  • Contraindication: The use of PDE-5 inhibitors and sGC stimulators is prohibited due to the risk of profound additive vasodilatory effects that cause severe hypotension.
  • Timing Restriction: A mandatory separation window is required following PDE-5 inhibitor use, which, depending on the specific agent, may be up to 48 hours before the administration of Nitroglycerin.
  • Exposure Alteration (Nitroglycerin): High-dose Aspirin (1000 mg) is documented to increase the systemic exposure (Cmax and AUC) of Nitroglycerin, enhancing its hemodynamic effects.
  • Exposure Alteration (Co-Drug): Intravenous Nitroglycerin reduces the anticoagulant effect of Heparin and decreases the thrombolytic effect of Alteplase, requiring monitoring of coagulation times when both are given intravenously. Oral Nitroglycerin also decreases the first-pass metabolism of Dihydroergotamine, leading to increased exposure.
  • Administration Note: Anticholinergic drugs may cause diminished salivary secretions, which can impair the dissolution and absorption of sublingual tablet forms.

This framework establishes explicit restrictions, primarily focusing on severe hypotensive potentiation, and details specific changes in drug concentrations when co-administered.

Mechanism of Action

How Angiocard Works: Mechanism of Action

Angiocard is a cardiovascular agent that exerts a specific action on key regulatory systems. Its mechanism of action involves highly specific molecular interactions that modulate specific physiological pathways, resulting in observable physiological changes.

Targeted Modulation of Adrenergic Signaling

Angiocard acts primarily as a selective antagonist for the beta-1 (beta1) adrenergic receptors located predominantly on cardiac tissue. This action physically blocks the ability of the body's natural signaling molecules (primarily norepinephrine) to bind and activate these receptors. This receptor interaction modifies the early molecular steps that shape systemic physiological effects.

Interference with Intracellular Signaling Cascades

By blocking the beta1 receptor, Angiocard immediately suppresses the subsequent intracellular signaling sequence. This intervention is applied in contexts involving specific pathway activation, preventing the signaling mediators from triggering the secondary messenger cascades (like cyclic AMP production) inside the cardiac muscle cells. This alters the signaling dynamics within the targeted pathways.

Regulation of Central Cardiac Activity

The overall mechanistic activity of Angiocard modulates the response of specific physiological pathways by adjusting activity within core cardiac regulatory systems. The receptor blockade alters signaling dynamics initiated by these mediators, ultimately leading to a reduction in both heart rate (negative chronotropy) and the force of contraction (negative inotropy), which results from its primary mechanism of action.

Dosage and Administration Information

How to Use Angiocard — Official Administration Guidelines

Instructions for using this class of cardiovascular medicine detail precise routes, dosage, and administration techniques.

Administration by Form:

Dosage Form Route of Administration Procedural Instruction
Sublingual Tablet/Powder Under the tongue (Sublingual) Allow to dissolve completely; do not chew, crush, or swallow. Do not rinse the mouth for 5 minutes after dosing.
Sustained-Release Capsule Oral (Swallow) Swallow the capsule whole; do not split, crush, or chew.
Intravenous (IV) Solution Continuous Infusion (Vein) Administer by slow continuous infusion; may require dilution before use.

Standard Dosing Rules:

  • Acute Use (Sublingual): One dose is administered at the first sign of discomfort. One additional dose may be taken every five minutes as needed. No more than three doses are recommended within a 15-minute period. If the situation is not relieved after three doses, prompt medical attention must be sought.
  • Scheduled Dosing (Oral): Dosing for sustained-release forms is typically administered twice daily (BID). If a regularly scheduled dose is missed, take it as soon as remembered unless it is close to the next scheduled time, in which case the missed dose should be skipped to prevent doubling the dose.
  • IV Titration: Intravenous therapy typically starts at a low rate (e.g., 5 mg/hr) and can be increased by small increments every 5 to 15 minutes, not to exceed the maximum labeled rate (e.g., 15 mg/hr), until the desired clinical effect is achieved.

Special Conditions:

Lower initial dosages may be required for certain patient populations, including the elderly or those with hepatic impairment, to minimize potential effects.

Recent Clinical Evidence

Research evidence / Overview of studies for Angiocard

Evidence for use in Major Depressive Disorder (MDD)

Research explored the measurements of Angiocard in adults with Major Depressive Disorder. The research primarily includes short-term Randomized Controlled Trials ( RCTs), typically over six to eight weeks. These trials monitored patient scores using standardized depression rating scales. The findings describe patterns observed in the studies where measurements of depression scale scores were recorded in the study populations. However, the evidence remains limited and heterogeneous, and results apply only to the populations studied.

Evidence for use in Generalized Anxiety Disorder (GAD)

Research explored the measurements of Angiocard in Generalized Anxiety Disorder, predominantly involving short-term RCTs. These studies research examined how scores on standardized anxiety scales change. The findings indicate measurements related to standardized anxiety scores were observed in some studies. The consistency of these measurements varied across some studies. Limited information exists regarding sustained measurements in anxiety beyond the short term, and the comparative evidence is lacking.

Evidence for use in Panic Disorder (PD) and Social Anxiety Disorder (SAD)

Research explored the measurements of Angiocard in studies for Panic Disorder and Social Anxiety Disorder. Data show patterns related to measurements in the number of panic attacks and in scores on social anxiety scales during the study periods. Uncertainty remains high due to limited follow-up durations, and evidence quality varies across studies.

Long-term Studies and Follow-up

Research exploring the long-term observation of Angiocard is ongoing, but the majority of existing RCTs research explored short-term symptom changes. Currently, long-term effects are not fully established because follow-up durations were limited. Limited information for long-term outcomes means that the durability of observed measurements over periods exceeding six months appears to be insufficiently characterized.

What is Still Uncertain about Angiocard

A key gap is the lack of fully established long-term effects, as the evidence is limited primarily to short-term studies. Evidence quality varies across studies, and findings were mixed, contributing to the complexity of interpreting the overall data. This section summarizes these gaps, highlighting that research provides context but not individual predictions.

Key Studies & References

  1. Long-Term Outcomes and Relapse Rates Following Acute Treatment of Anxiety Disorders: A Review
  2. Psychotropic Medications: Use in Pediatric and Geriatric Populations - Safety and Efficacy Considerations

Frequently Asked Questions (FAQ)

Common questions about Angiocard (FAQ)

Q: How quickly am I supposed to feel a difference after starting Angiocard?

A: According to the official product information for the sublingual form (tablet or spray, taken under the tongue), the onset of the effect is generally very rapid. Regulatory documents state that the desired vasodilatory effect, which helps relieve chest discomfort, typically begins within one to three minutes after administration.

Q: Can Angiocard make you feel dizzy or lightheaded?

A: Yes, dizziness and lightheadedness are reported adverse effects. This medication is a vasodilator (it widens blood vessels), which can sometimes cause a drop in blood pressure, leading to lightheadedness, particularly when standing up quickly. Regulatory documents indicate that caution may be warranted due to these potential effects.

Q: Is it normal to have a slight headache when you first start taking Angiocard?

A: Yes, headache is the most frequently reported side effect of this medication. The official product labeling indicates these headaches can be severe and may recur with each dose. This effect is generally understood to be a consequence of the drug's primary action (vasodilation) and is the most commonly reported side effect.

Q: Why do some people say Angiocard makes them tired?

A: While tiredness or fatigue is not always listed as a common side effect in regulatory documents, it can be indirectly linked to the drug's action. Extreme symptoms like weakness or tiredness may be reported alongside conditions such as orthostatic hypotension (a drop in blood pressure upon standing) or, in rare cases, as symptoms of an overdose.

Q: How long after taking Angiocard should I wait to drive?

A: Caution is advised when performing tasks that require full focus, such as driving or operating machinery. Because this medication can cause side effects like dizziness, lightheadedness, or fainting (syncope) due to lowered blood pressure, patients are generally advised to wait until the effects are known before engaging in these activities.

Q: Does Angiocard need to be taken at the exact same time every day?

A: For forms taken on a schedule, such as sustained-release capsules, maintaining a consistent dosing routine is important. Regulatory documents emphasize the need for a daily 'nitrate-free interval', and the doses must be scheduled to allow for a period without the drug in the body. This strategy is essential to prevent the body from becoming tolerant to the medication's effects.

Q: Can you just stop taking Angiocard, or do you have to taper off?

A: Discontinuing the medication requires the guidance of a healthcare professional. Official warnings and precautions note that in certain long-term, high-dose uses, physical dependence may occur. Abrupt withdrawal has been associated with serious symptoms like severe chest pain, suggesting the medication should be slowly reduced over time.

Q: Are there any specific foods I should avoid while on Angiocard?

A: Regulatory documents list alcohol (ethanol) as the primary substance that interacts with Angiocard, due to the risk of dangerously lowering blood pressure. Outside of alcohol, there are no mandatory restrictions on specific foods listed in the official labeling.

Q: Can Angiocard cause swelling in the ankles or feet?

A: Although the official labeling for this medication focuses on severe adverse reactions, swelling (edema) is a generally recognized effect of potent vasodilators. By widening the blood vessels, the drug can cause blood to pool in the extremities, sometimes leading to swelling in the ankles or feet.

Q: Why is Angiocard prescribed sometimes for people who don't have severe symptoms?

A: The drug is indicated for two main uses: the acute relief of an attack of chest discomfort and the prophylaxis (prevention) of an attack. Therefore, it is often prescribed to be taken 5 to 10 minutes before engaging in strenuous activities that are known to bring on chest discomfort.

Q: Does Angiocard affect kidney function?

A: The medication should be used with caution in patients with pre-existing organ problems. The official labeling specifies that patients with severe renal insufficiency (kidney impairment) require additional monitoring. This is because reduced kidney function can affect how the body processes the drug.

Q: Can Angiocard cause stomach upset or nausea?

A: Yes, regulatory documents list nausea and vomiting among the potential symptoms. These symptoms are typically associated with an overdose or a severe drop in blood pressure caused by the medication.

Q: Are the side effects of Angiocard worse for older patients?

A: Official information states that older adults are eligible but require caution when initiating treatment. This is due to a greater likelihood of age-related issues, such as decreased renal, hepatic, or cardiac function. A lower starting dosage may be required to minimize potential side effects in this population.

Q: Can Angiocard be crushed or split in half?

A: This depends entirely on the formulation. The sublingual tablet must not be chewed, crushed, or swallowed. If a sustained-release capsule is used, official instructions state the capsule must be swallowed whole and not split, crushed, or chewed, as this would interfere with the controlled-release mechanism.

Q: How long does the effect of one dose of Angiocard last?

A: The duration of effect varies by the form used. For the common sublingual tablet, the drug's therapeutic effects persist for at least 25 minutes after a single dose. Other formulations, like the transdermal patch, are designed to provide a much longer, sustained systemic effect.

Q: What happens if Angiocard is taken with alcohol?

A: Alcohol is listed in the official product information as a substance that can cause additive effects in lowering blood pressure. This severe drop can lead to or worsen symptoms such as headache, dizziness, lightheadedness, and the risk of fainting.

Q: What if I miss a dose of Angiocard?

A: If a patient is on a scheduled regimen and remembers a missed dose, the general guidance is to take it right away. However, if it is already close to the time of the next scheduled dose, regulatory guidance advises that the missed dose should be skipped entirely and the patient should return to the regular schedule. This is done to prevent taking a double dose.

Q: Does Angiocard interact with common cold or flu medicines?

A: Common cold and flu medicines can contain various ingredients that may interact with Angiocard. Some ingredients may cause moderate or minor interactions that affect the blood pressure-lowering effect. Regulatory documents recommend checking all components of cold and flu medicines with a professional to assess the potential for interaction.

Q: Does Angiocard help improve circulation?

A: Yes, its primary function is directly related to circulation. The medication is a vasodilator, meaning it causes the relaxation of vascular smooth muscle and the widening of blood vessels. This action improves the overall balance of oxygen supply and demand for the heart muscle by reducing its workload.

Q: Does Angiocard cause dry mouth?

A: Yes, official patient information documents indicate that drying of the mouth has been reported with the use of this medication. If this occurs and is bothersome, it is an effect that should be discussed with a healthcare provider.

Q: Is it possible to be allergic to Angiocard?

A: Yes, the medication is contraindicated (must not be used) in patients with a known hypersensitivity to nitrates or any other component of the formulation. Although allergic reactions are rare, patients should be monitored for any signs of such a reaction.

How should Angiocard be stored and disposed of?

How to Store and Dispose of Angiocard (Nitroglycerin)

The effectiveness of Angiocard depends strictly on proper storage as defined in regulatory labeling.

Storage Conditions

Dosage Form Required Storage Conditions
Oral/Transdermal Controlled Room Temperature (20 C to 25 C). Protect from heat, light, and moisture.
Sublingual Tablets Must remain in the original, tightly closed glass container to prevent potency loss.
Prohibitions Do not freeze all forms; do not refrigerate transdermal patches.

All forms of this medication must be kept out of the sight and reach of children.

Disposal

Used transdermal patches must be folded in half with the sticky sides together before being safely discarded. Expired or unused medication should be disposed of according to official local regulations, often via a drug take-back program, to prevent accidental exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Angiocard found in:

A-Z Index: